天疱疮发病机制和靶向治疗的研究进展

doi:10.35541/cjd.20210248

中华皮肤科杂志 ›› 2024, Vol. 57 ›› Issue (4): 374-378.doi: 10.35541/cjd.20210248

天疱疮发病机制和靶向治疗的研究进展

严汝帆¹ 廖洁月² 郭子瑜² 姚南² 周文玉² 罗帅寒天² 张桂英² 赵明²

¹深圳市宝安区石岩人民医院，深圳 518000；²中南大学湘雅二医院皮肤科，长沙 410011

收稿日期:2021-03-24 修回日期:2021-12-22 发布日期:2024-04-07
通讯作者: 罗帅寒天；张桂英 E-mail:lsht5309@csu.edu.cn; lindazgy@ csu.edu.cn
基金资助:
国家自然科学基金（81703133）；湖南省自然科学基金（2019JJ40448、2021JJ40856）

Pathogenesis and targeted therapy of pemphigus

Yan Rufan¹, Liao Jieyue², Guo Ziyu², Yao Nan², Zhou Wenyu², Luo Shuaihantian², Zhang Guiying², Zhao Ming²

¹Shenzhen Baoan Shiyan People′s Hospital, Shenzhen 518000, Guangdong,China; ²Department of Dermatology, the Second Xiangya Hospital of Central South University, Changsha 410011, China

Received:2021-03-24 Revised:2021-12-22 Published:2024-04-07
Contact: Luo Shuaihantian; Zhang Guiying E-mail:lsht5309@csu.edu.cn; lindazgy@ csu.edu.cn
Supported by:
National Natural Science Foundation of China（81703133）; Natural Science Foundation of Hunan Province of China （2019JJ40448, 2021JJ40856）

摘要/Abstract

摘要： 【摘要】近年来随着对天疱疮研究的深入，在桥粒芯蛋白抗体所致的免疫反应机制的基础上，又发现了新的发病机制，同时靶向治疗也取得了很多进展。本文综述近年来有关天疱疮的发病机制及靶向治疗药物的进展。

关键词: 天疱疮, 分子靶向治疗, 生物制剂, 发病机制

Abstract: 【Abstract】 In recent years, with the in-depth study of pemphigus, new pathogenesis has been identified based on the desmoglein antibody-mediated immune response mechanism, and new progress has been made in targeted therapy. This review summarizes recent advances in the pathogenesis and targeted therapy of pemphigus.

Key words: Pemphigus, Molecular targeted therapy, Biological agents, Pathogenesis

严汝帆廖洁月郭子瑜姚南周文玉罗帅寒天张桂英赵明. 天疱疮发病机制和靶向治疗的研究进展[J]. 中华皮肤科杂志, 2024,57(4):374-378. doi:10.35541/cjd.20210248

Yan Rufan, Liao Jieyue, Guo Ziyu, Yao Nan, Zhou Wenyu, Luo Shuaihantian, Zhang Guiying, Zhao Ming. Pathogenesis and targeted therapy of pemphigus[J]. Chinese Journal of Dermatology, 2024, 57(4): 374-378.doi:10.35541/cjd.20210248

参考文献 45

［1］	Kridin K. Pemphigus group: overview, epidemiology, mortality, and comorbidities［J］. Immunol Res, 2018,66（2）:255⁃270. doi: 10.1007/s12026⁃018⁃8986⁃7.
［2］	Sinha AA, Sajda T. The evolving story of autoantibodies in pemphigus vulgaris: development of the "super compensation hypothesis"［J］. Front Med （Lausanne）, 2018,5:218. doi: 10. 3389/fmed.2018.00218.
［3］	Melchionda V, Harman KE. Pemphigus vulgaris and pemphigus foliaceus: an overview of the clinical presentation, investigations and management［J］. Clin Exp Dermatol, 2019,44（7）:740⁃746. doi: 10.1111/ced.14041.
［4］	Hashimoto T, Amagai M, Watanabe K, et al. A case of pemphigus vulgaris showing reactivity with pemphigus antigens （Dsg1 and Dsg3） and desmocollins［J］. J Invest Dermatol, 1995,104（4）:541⁃544. doi: 10.1111/1523⁃1747.ep12606050.
［5］	Lotti R, Atene CG, Marconi A, et al. Development of a desmocollin⁃3 active mouse model recapitulating human atypical pemphigus［J］. Front Immunol, 2019,10:1387. doi: 10. 3389/fimmu.2019.01387.
［6］	Grando SA. Cholinergic control of epidermal cohesion［J］. Exp Dermatol, 2006,15（4）:265⁃282. doi: 10.1111/j.0906⁃6705.2006. 00410.x.
［7］	Lakshmi M, Jaisankar TJ, Rajappa M, et al. Correlation of antimuscarinic acetylcholine receptor antibody titers and antidesmoglein antibody titers with the severity of disease in patients with pemphigus［J］. J Am Acad Dermatol, 2017,76（5）:895⁃902. doi: 10.1016/j.jaad.2016.11.039.
［8］	Chernyavsky A, Chen Y, Wang PH, et al. Pemphigus vulgaris antibodies target the mitochondrial nicotinic acetylcholine receptors that protect keratinocytes from apoptolysis［J］. Int Immunopharmacol, 2015,29（1）:76⁃80. doi: 10.1016/j.intimp. 2015.04.046.
［9］	Vincent A. Unravelling the pathogenesis of myasthenia gravis［J］. Nat Rev Immunol, 2002,2（10）:797⁃804. doi: 10.1038/nri916.
［10］	Rakocević⁃Stojanović V, Rakocević I, Perić S, et al. Intravenous immunoglobulin therapy in two patients with myasthenia gravis and pemphigus vulgaris［J］. Acta Myol, 2009,28（3）:101⁃102.
［11］	Bhatia SM, Streilein RD, Hall RP. Correlation of IgG autoantibodies against acetylcholine receptors and desmogleins in patients with pemphigus treated with steroid sparing agents or rituximab［J］. PLoS One, 2020,15（6）:e0233957. doi: 10.1371/journal.pone.0233957.
［12］	Zhang F, Yan X, Jiang D, et al. Eight novel mutations of ATP2C1 identified in 17 Chinese families with Hailey⁃Hailey disease［J］. Dermatology, 2007,215（4）:277⁃283. doi: 10.1159/000107620.
［13］	Malan M, Xuejingzi W, Si J, et al. Hailey⁃Hailey disease: the role of azathioprine an immunomodulator［J］. Pan Afr Med J, 2019,32:65. doi: 10.11604/pamj.2019.32.65.17877.
［14］	Kalantari⁃Dehaghi M, Anhalt GJ, Camilleri MJ, et al. Pemphigus vulgaris autoantibody profiling by proteomic technique［J］. PLoS One, 2013,8（3）:e57587. doi: 10.1371/journal.pone.0057587.
［15］	Kugelmann D, Rötzer V, Walter E, et al. Role of Src and cortactin in pemphigus skin blistering［J］. Front Immunol, 2019,10:626. doi: 10.3389/fimmu.2019.00626.
［16］	Walter E, Vielmuth F, Rotkopf L, et al. Different signaling patterns contribute to loss of keratinocyte cohesion dependent on autoantibody profile in pemphigus［J］. Sci Rep, 2017,7（1）:3579. doi: 10.1038/s41598⁃017⁃03697⁃7.
［17］	Petzl⁃Erler ML. Beyond the HLA polymorphism: a complex pattern of genetic susceptibility to pemphigus［J］. Genet Mol Biol, 2020,43（3）:e20190369. doi: 10.1590/1678⁃4685⁃gmb⁃2019⁃0369.
［18］	Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 Guideline for diagnosis and treatment⁃⁃guided by the European Dermatology Forum （EDF） in cooperation with the European Academy of Dermatology and Venereology （EADV）［J］. J Eur Acad Dermatol Venereol, 2015,29（3）:405⁃414. doi: 10.1111/jdv.12772.
［19］	夏登梅, 闫薇, 徐飞, 等. HLA⁃DRB1等位基因与四川汉族人寻常型天疱疮的相关性研究［J］. 中华皮肤科杂志, 2017,50（8）:589⁃591. doi: 10.3760/cma.j.issn.0412⁃4030.2017.08.010.
［20］	Zhang SY, Zhou XY, Zhou XL, et al. Subtype⁃specific inherited predisposition to pemphigus in the Chinese population［J］. Br J Dermatol, 2019,180（4）:828⁃835. doi: 10.1111/bjd.17191.
［21］	Mahmoudi H, Ebrahimi E, Daneshpazhooh M, et al. Single⁃nucleotide polymorphisms associated with pemphigus vulgaris: Potent markers for better treatment and personalized medicine［J］. Int J Immunogenet, 2020,47（1）:41⁃49. doi: 10.1111/iji. 12451.
［22］	Fang SY, Li CL, Liu XS, et al. Correlation between polymorphisms of the NR3C1 gene and glucocorticoid effectiveness in patients with pemphigus vulgaris［J］. Sci Rep, 2017,7（1）:11890. doi: 10.1038/s41598⁃017⁃12255⁃0.
［23］	Egu DT, Walter E, Spindler V, et al. Inhibition of p38MAPK signalling prevents epidermal blistering and alterations of desmosome structure induced by pemphigus autoantibodies in human epidermis［J］. Br J Dermatol, 2017,177（6）:1612⁃1618. doi: 10.1111/bjd.15721.
［24］	Vielmuth F, Walter E, Fuchs M, et al. Keratins regulate p38MAPK⁃dependent desmoglein binding properties in pemphigus［J］. Front Immunol, 2018,9:528. doi: 10.3389/fimmu.2018.00528.
［25］	Chatzikyriakidou A, Voulgari PV, Georgiou I, et al. The role of microRNA⁃146a （miR⁃146a） and its target IL⁃1R⁃associated kinase （IRAK1） in psoriatic arthritis susceptibility［J］. Scand J Immunol, 2010,71（5）:382⁃385. doi: 10.1111/j.1365⁃3083.2010. 02381.x.
［26］	Zhai Y, Xu K, Leng RX, et al. Association of interleukin⁃1 receptor⁃associated kinase （IRAK1） gene polymorphisms （rs3027898, rs1059702） with systemic lupus erythematosus in a Chinese Han population［J］. Inflamm Res, 2013,62（6）:555⁃560. doi: 10.1007/s00011⁃013⁃0607⁃2.
［27］	Chatzikyriakidou A, Kyriakou A, Meltzanidou P, et al. Association of NFKB1 ⁃94ATTG ins/del polymorphism （rs28362491） with pemphigus vulgaris［J］. Exp Dermatol, 2019,28（8）:972⁃975. doi: 10.1111/exd.13957.
［28］	Fetter T, Niebel D, Braegelmann C, et al. Skin⁃associated B cells in the pathogenesis of cutaneous autoimmune diseases⁃implications for therapeutic approaches［J］. Cells, 2020,9（12）:2627. doi: 10.3390/cells9122627.
［29］	Mélet J, Mulleman D, Goupille P, et al. Rituximab⁃induced T cell depletion in patients with rheumatoid arthritis: association with clinical response［J］. Arthritis Rheum, 2013,65（11）:2783⁃2790. doi: 10.1002/art.38107.
［30］	Joly P, Maho⁃Vaillant M, Prost⁃Squarcioni C, et al. First⁃line rituximab combined with short⁃term prednisone versus prednisone alone for the treatment of pemphigus （Ritux 3）: a prospective, multicentre, parallel⁃group, open⁃label randomised trial［J］. Lancet, 2017,389（10083）:2031⁃2040. doi: 10.1016/S0140⁃6736（17）30070⁃3.
［31］	Karatzi C, Stefanidou M, Islamidou E, et al. Beware of anal fissures: pemphigus vulgaris of the anal canal［J］. Ann Gastroenterol, 2019,32（2）:205⁃207. doi: 10.20524/aog.2018.0340.
［32］	Gupta J, Raval RC, Shah AN, et al. Low⁃dose rituximab as an adjuvant therapy in pemphigus［J］. Indian J Dermatol Venereol Leprol, 2017,83（3）:317⁃325. doi: 10.4103/ijdvl.IJDVL_1078_14.
［33］	Kridin K, Kowalski EH, Kneiber D, et al. From bench to bedside: evolving therapeutic targets in autoimmune blistering disease［J］. J Eur Acad Dermatol Venereol, 2019,33（12）:2239⁃2252. doi: 10.1111/jdv.15816.
［34］	Pharmaceuticals N. Efficacy and safety of ofatumumab in treatment of pemphigus vulgaris［DB/OL］. （2019⁃06⁃06）［2021⁃04⁃02］. https://clinicaltrials.gov/ct2/show/NCT01920477.
［35］	Nagel A, Podstawa E, Eickmann M, et al. Rituximab mediates a strong elevation of B⁃cell⁃activating factor associated with increased pathogen⁃specific IgG but not autoantibodies in pemphigus vulgaris［J］. J Invest Dermatol, 2009,129（9）:2202⁃2210. doi: 10.1038/jid.2009.27.
［36］	Kowalczyk⁃Quintas C, Chevalley D, Willen L, et al. Inhibition of membrane⁃bound BAFF by the anti⁃BAFF antibody belimumab［J］. Front Immunol, 2018,9:2698. doi: 10.3389/fimmu.2018. 02698.
［37］	Feliciani C, Toto P, Amerio P, et al. In vitro and in vivo expression of interleukin⁃1alpha and tumor necrosis factor⁃alpha mRNA in pemphigus vulgaris: interleukin⁃1alpha and tumor necrosis factor⁃alpha are involved in acantholysis［J］. J Invest Dermatol, 2000,114（1）:71⁃77. doi: 10.1046/j.1523⁃1747.2000. 00835.x.
［38］	Kaya Erdogan H, Yuksel Canakci N, Acer E, et al. Successful treatment of pemphigus foliaceous and ankylosing spondylitis with infliximab and methotrexate: a case report［J］. Dermatol Ther, 2020,33（4）:e13801. doi: 10.1111/dth.13801.
［39］	Andrés TS, Alexandro B, de Oca⁃Sánchez Griselda M, et al. Etanercept plus methotrexate: an effective combination therapy for recalcitrant pemphigus vulgaris［J］. J Res Med Sci, 2015,20（3）:317.
［40］	Didona D, Fania L, Di Zenzo G, et al. Erythromycin⁃induced pemphigus foliaceus successfully treated with etanercept［J］. Dermatol Ther, 2020,33（6）:e14201. doi: 10.1111/dth.14201.
［41］	Siddiqi HF, Staser KW, Nambudiri VE. Research techniques made simple: CAR T⁃cell therapy［J］. J Invest Dermatol, 2018,138（12）:2501⁃2504.e1. doi: 10.1016/j.jid.2018.09.002.
［42］	Prasad V. Immunotherapy: tisagenlecleucel ⁃ the first approved CAR⁃T⁃cell therapy: implications for payers and policy makers［J］. Nat Rev Clin Oncol, 2018,15（1）:11⁃12. doi: 10.1038/nrclinonc.2017.156.
［43］	Clark RA. Slamming the brakes on lupus with CAR T cells［J］. Sci Immunol, 2019,4（34）:eaax3916. doi: 10.1126/sciimmunol.aax3916.
［44］	McHugh J. CAR T cells drive out B cells in SLE［J］. Nat Rev Rheumatol, 2019,15（5）:249. doi: 10.1038/s41584⁃019⁃0214⁃x.
［45］	Bio C. Open⁃label study to determine the maximum tolerated dose of DSG3⁃CAART in mucosal⁃dominant PV patients （mPV）［DB/OL］. （2020⁃01⁃26）［2021⁃04⁃02］. https://clinicaltrials.gov/ct2/show/NCT04422912.

[1]	丁瑞张卫亮李静陈羽佳李珺莹. 度普利尤单抗治疗5例难治性内源性角化型手足部湿疹[J]. 中华皮肤科杂志, 2024, 0(4): 20230429-e20230429.
[2]	宋雨晴杨楠刘琳琳冯子仪韩世新周梅娟. [开放获取] 皮肤磨削术治疗家族性良性慢性天疱疮6例临床观察[J]. 中华皮肤科杂志, 2024, 0(4): 20220278-e20220278.
[3]	岳淑珍树叶罗鸯鸯李珂瑶张圆圆汤建萍韦祝. 奥马珠单抗治疗儿童慢性荨麻疹的疗效和安全性回顾研究[J]. 中华皮肤科杂志, 2024, 57(4): 354-358.
[4]	鞠强李嘉祺. [开放获取] 寻常痤疮再认识：从发病机制到治疗策略[J]. 中华皮肤科杂志, 2024, 57(4): 289-294.
[5]	宗杨永怡马楚君苏忠兰. 银屑病生物制剂治疗后湿疹化发生机制及应对策略[J]. 中华皮肤科杂志, 2024, 0(3): 20220578-e20220578.
[6]	姚我汪慧英. [开放获取] 拉那利尤单抗治疗遗传性血管性水肿临床试验的系统综述[J]. 中华皮肤科杂志, 2024, 0(3): 20230378-e20230378.
[7]	刘亭微孟潇琦顾多多潘婼芯张悦许阳. 玫瑰痤疮发病机制的研究进展[J]. 中华皮肤科杂志, 2024, 57(2): 186-190.
[8]	中国医师协会皮肤科医师分会中华医学会皮肤性病学分会中国医疗保健国际交流促进会皮肤医学分会疑难重症及罕见病国家重点实验室国家皮肤与免疫疾病临床医学研究中心. 特应性皮炎治疗药物应用管理专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(2): 97-108.
[9]	郭蕾曹春艳方晓雅冯素英. 自身免疫性大疱病患者创面感染多重耐药菌现况及危险因素分析[J]. 中华皮肤科杂志, 2024, 57(2): 155-160.
[10]	窦进法王建波张帅李建国刘鸿伟张守民. 新型冠状病毒感染疫情期间接受生物制剂治疗的中重度斑块状银屑病患者病情变化及影响因素分析：单中心横断面研究[J]. 中华皮肤科杂志, 2024, 0(2): 20230167-e20230167.
[11]	宋志强陈奇权葛兰. 从特应性皮炎发病机制谈靶向治疗进展[J]. 中华皮肤科杂志, 2023, 56(8): 718-723.
[12]	周彤耿松梅. 生物制剂在大疱性类天疱疮治疗中的应用[J]. 中华皮肤科杂志, 2023, 56(8): 789-793.
[13]	闪莹常晓彤左亚刚. 自身免疫性疱病的表位扩展现象[J]. 中华皮肤科杂志, 2023, 56(7): 702-705.
[14]	梁云生黎展宏伍奕蓓. [开放获取] 从发病机制认知变化看慢性自发性荨麻疹治疗进展[J]. 中华皮肤科杂志, 2023, 56(6): 552-558.
[15]	杨娜丽许秋阳吴含文叶雅慧朱吉玲刘晶晶李智铭. [开放获取] 奥马珠单抗治疗慢性荨麻疹的疗效和安全性回顾性分析[J]. 中华皮肤科杂志, 2023, 56(6): 518-524.

天疱疮发病机制和靶向治疗的研究进展

Pathogenesis and targeted therapy of pemphigus

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 45

相关文章 15

Metrics

本文评价

推荐阅读 10